Early stage triple negative breast cancer research hub

A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers

This study looks at new ways to treat early-stage triple-negative breast cancer. It tests a drug called nivolumab alongside standard chemotherapy to see if it helps shrink tumours more effectively before surgery. The aim is to improve treatment results for this type of breast cancer.